TRex Bio (NASDAQ:TRXB) Stock Picked Up by Analysts at Evercore

Equities researchers at Evercore assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a research report issued on Tuesday, Zacks reports. The brokerage set a “strong-buy” rating on the stock.

Several other research firms have also commented on TRXB. Wedbush assumed coverage on TRex Bio in a report on Monday. They set an “outperform” rating and a $30.00 target price for the company. Stifel Nicolaus initiated coverage on shares of TRex Bio in a research note on Tuesday. They set a “buy” rating and a $39.00 target price on the stock. Cantor Fitzgerald began coverage on TRex Bio in a research note on Tuesday. They issued an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of TRex Bio in a research report on Tuesday. They issued an “overweight” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $29.67.

TRex Bio Stock Performance

TRXB opened at $13.55 on Tuesday. TRex Bio has a fifty-two week low of $12.50 and a fifty-two week high of $16.56.

Insiders Place Their Bets

In other TRex Bio news, major shareholder Alexandria Venture Investments bought 178,571 shares of TRex Bio stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the acquisition, the insider owned 1,346,501 shares of the company’s stock, valued at approximately $18,851,014. This represents a 15.29% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.